Allurion rises on plan to offer discounted weight-loss drug Mounjaro in Argentina
03/02/2026 14:50
** Shares of healthcare firm Allurion Technologies ALUR.N rise 6.19% to $1.31
** Co says it partnered with Argentine companies Bionut and Farmastar to offer discounted access to Eli Lilly's LLY.N weight-loss pill, Mounjaro, alongside ALUR's swallowable Smart Capsule in Argentina
** The Smart Capsule is a tiny pill that can track pH, temperature or gut biomarkers from inside the digestive tract to monitor gut health - co
** Co says a study of 76 patients combining low‑dose Mounjaro with its capsule led to 23% average weight loss over one year, with lower side effects and no dropouts
** Co says the Smart Capsule is not yet approved in the U.S.; it is exploring similar tie‑ups in other countries
** Shares of ALUR fell ~89% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Recent news on Allurion Technologies
See all newsBrief: Allurion Technologies Inc - Sees Growing Demand From Patients Discontinuing Glp-1 Therapy
Brief: Allurion Intends To Appeal NYSE Notice Of Delisting, Execute Plan To Regain Compliance, And Expects To Continue Trading On NYSE
Brief: NYSE To Commence Delisting Proceedings Against Allurion Technologies, Inc.
Allurion rises on plan to offer discounted weight-loss drug Mounjaro in Argentina
Allurion rises after strong weight-loss data from combination therapy